Abstract:Rett syndrome (RTT, OMIM # 312750), a neurodevelopmental disorder of early childhood, is primarily caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MECP2). Various molecular functions have been ascribed to MECP2, including the regulation of histone modifications associated with repressive chromatin remodeling, but the role of these mechanisms for the pathophysiology of RTT remains unclear. Here, we explore whether or not neuronal expression of the histone H3-lysine 9 specific methyl-transferase, Setdb1 (Set domain, bifurcated 1)/Eset/Kmt1e, which is normally present only at low levels in differentiated neurons, rescues the RTT-like phenotype of Mecp2-deficient mice. A myc-tagged Setdb1 cDNA was expressed through the tau locus for ubiquitous expression in CNS neurons, or under control of the calcium/calmodulin-dependent protein kinase II (CK) promoter to selectively target postmitotic neurons in forebrain. However, the CK-Setdb1 transgene lead to an enhanced neurological deficit, and the tauSetdb1 allele further shortened life span of mice with a brain-wide deletion of Mecp2 during prenatal development. In contrast, no neurological deficits or premature death was observed in CK-Setdb1 and tauSetdb1 mice expressing wildtype Mecp2. However, levels of trimethylated H3K9 at pericentromeric repeats were fully maintained in differentiated neurons from symptomatic Mecp2 null mutant mice. Based on these results, we draw two conclusions: First, neuronal chromatin in RTT brain is not affected by a generalized deficit in H3K9 trimethylation. Second, artificial up-regulation of this repressive chromatin mark via Setdb1 gene delivery specifically to neurons is harmful for the Mecp2-deficient brain. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

The methyl-CpG-binding domain (MBD) is crucial for MeCP2's dysfunction-induced defects in adult newborn neurons.

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

Loss of MeCP2 in immature neurons leads to impaired network integration.

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

MeCP2 links heterochromatin condensates and neurodevelopmental disease

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

MeCP2 and neurodevelopmental disorders

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

SUMOylation of MeCP2 is essential for transcriptional repression and hippocampal synapse development.

Setdb1-mediated Histone H3K9 Hypermethylation in Neurons Worsens the Neurological Phenotype of Mecp2-deficient Mice